Short Interest in Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Grows By 220.0%

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) was the target of a significant increase in short interest during the month of March. As of March 13th, there was short interest totaling 186,549 shares, an increase of 220.0% from the February 26th total of 58,304 shares. Currently, 2.7% of the company’s shares are sold short. Based on an average daily volume of 710,018 shares, the short-interest ratio is presently 0.3 days. Based on an average daily volume of 710,018 shares, the short-interest ratio is presently 0.3 days. Currently, 2.7% of the company’s shares are sold short.

Hedge Funds Weigh In On Calidi Biotherapeutics

Several hedge funds have recently bought and sold shares of the business. DRW Securities LLC bought a new stake in shares of Calidi Biotherapeutics during the fourth quarter worth $173,000. Geode Capital Management LLC boosted its stake in shares of Calidi Biotherapeutics by 41.7% during the fourth quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock valued at $49,000 after purchasing an additional 12,334 shares during the period. Virtu Financial LLC bought a new position in shares of Calidi Biotherapeutics in the fourth quarter worth about $25,000. Finally, Warberg Asset Management LLC purchased a new position in Calidi Biotherapeutics in the 3rd quarter worth about $28,000. Institutional investors own 12.53% of the company’s stock.

Calidi Biotherapeutics Trading Up 0.9%

Shares of NYSEAMERICAN:CLDI traded up $0.00 during trading hours on Wednesday, hitting $0.29. 149,737 shares of the company’s stock traded hands, compared to its average volume of 222,331. The business has a fifty day moving average price of $0.74 and a 200-day moving average price of $1.21. Calidi Biotherapeutics has a 1 year low of $0.27 and a 1 year high of $19.20. The company has a quick ratio of 2.12, a current ratio of 2.12 and a debt-to-equity ratio of 0.11.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.